Sutimlimab in Patients With Cold Agglutinin Disease ( CAD ): Results From a Managed Access Program
European Journal of Haematology · 2025
DOI: 10.1111/ejh.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Sandra Maria Frey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cold agglutinin disease (CAD) is a low‐grade lymphoproliferative disorder accounting for 15%–30% of patients suffering from autoimmune hemolytic anemias. The clonal B cells produce autoantibodies primarily of the IgM‐κ class that cause agglutination of red blood cells (RBCs) at temperatures ≤ 37°C and activate the classical complement pathway with subsequent RBC destruction. Before the approval of the monoclonal antibody sutimlimab, treatment options were limited. Sutimlimab inhibits the classical complement pathway at C1s while sparing the lectin and alternative complement pathways. Efficacy, safety and tolerability of sutimlimab have been established in the multicenter CARDINAL and CADENZA trials. In the present investigation, 10 patients on sutimlimab were followed up to 96 weeks in the Managed Access Program (MAP) in Essen. Eight of these patients had previously participated in the multicenter trials and were restarted on sutimlimab after a median washout period of 12.6 weeks. In addition, two sutimlimab‐naive patients were included. Hemoglobin concentration increased in all patients (median hemoglobin concentration before therapy 9.8 vs. 12.5 g/dL at the end of the study). Bilirubin levels normalized already after 2 weeks in all patients. Reticulocyte count declined in nine, haptoglobin and hemopexin concentrations normalized in six and 10 patients, respectively. In conclusion, the present investigation with primary CAD patients in a single center demonstrates long‐term normalization of laboratory parameters, abrogation of specific clinical symptoms and absence of drug‐related side effects with sutimlimab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Sandra Maria Frey, Ferras Alashkar, Veronika Lenz, H Christian Reinhardt, Alexander Röth
Zitieren
APA
Frey, S. M., Halberstadt, P., Alashkar, F., Lenz, V., Reinhardt, H. C., & Röth, A. (2025). Sutimlimab in Patients With Cold Agglutinin Disease ( CAD ): Results From a Managed Access Program. European Journal of Haematology. https://doi.org/10.1111/ejh.70068
Vancouver
Frey SM, Halberstadt P, Alashkar F, Lenz V, Reinhardt HC, Röth A. Sutimlimab in Patients With Cold Agglutinin Disease ( CAD ): Results From a Managed Access Program. European Journal of Haematology. 2025. doi:10.1111/ejh.70068
BibTeX
@article{Frey2025,
author = {Frey, Sandra Maria and Halberstadt, Pauline and Alashkar, Ferras and Lenz, Veronika and Reinhardt, H Christian and Röth, Alexander},
title = {Sutimlimab in Patients With Cold Agglutinin Disease ( CAD ): Results From a Managed Access Program},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.70068}
}
EUVIMED